Experience With Carbon Ion Radiotherapy for WHO Grade 2 Diffuse Astrocytomas
- Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba (Japan)
- Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba (Japan)
- Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma (Japan)
- Department of Neurological Surgery, Saitama Medical University, Saitama (Japan)
- Department of Neurological Surgery, Tokyo Women's Medical University, Tokyo (Japan)
Purpose: To assess outcomes of carbon ion radiotherapy for diffuse astrocytomas in adults. Methods and Materials: Between October 1994 and February 2002, 14 patients with diffuse astrocytoma, identified as eligible for carbon ion radiotherapy, were enrolled in a phase I/II clinical trial. Carbon ion radiotherapy was administered in 24 fractions over 6 weeks. The normal tissue morbidity was monitored carefully, and the carbon ion dose was escalated from 50.4 Gy equivalent (GyE) to 55.2 GyE. Patients were divided into two groups according to their carbon ion doses: a low-dose group in which 2 patients were irradiated with 46.2 GyE and 7 patients were irradiated with 50.4 GyE, and a high-dose group in which 5 patients were irradiated with 55.2 GyE. Results: Toxicities were within acceptable limits, and none of the patients developed Grade 3 or higher acute or late reactions. The median progression-free survival (PFS) time was 18 months for the low-dose group and 91 months for the high-dose group (p = 0.0030). The median overall survival (OS) time was 28 months for the low-dose group and not reached for the high-dose group (p = 0.0208). Conclusion: High-dose group patients showed significant improvement in PFS and OS rates compared to those in the low-dose group, and both dose groups showed acceptable toxicity.
- OSTI ID:
- 22056309
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 83, Issue 1; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Phase I/II Clinical Trial of Carbon Ion Radiotherapy for Malignant Gliomas: Combined X-Ray Radiotherapy, Chemotherapy, and Carbon Ion Radiotherapy
Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen